ホーム>>Analytical Standards>>C16 Ceramide-d7 (d18:1-d7/16:0)

C16 Ceramide-d7 (d18:1-d7/16:0) (Synonyms: Cer-d7 (d18:1-d7/16:0), Ceramide-d7 (d18:1-d7/16:0), N-hexadecanoyl-D-erythro-Sphingosine-d7)

カタログ番号GC46976

C-16セラミドの定量化のための内部標準

Products are for research use only. Not for human use. We do not sell to patients.

C16 Ceramide-d7 (d18:1-d7/16:0) 化学構造

Cas No.: 1840942-13-3

サイズ 価格 在庫数 個数
500 μg
$512.00
在庫あり
1 mg
$922.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents

C16 Ceramide-d7 is intended for use as an internal standard for the quantification of C16 ceramide by GC- or LC-MS. C16 Ceramide is an endogenous ceramide, generated by ceramide synthase 6 (CerS6), that acts as a lipid second messenger to regulate apoptosis and stress signaling.1 Accumulation of C16 ceramide through PPMP (30 μM) or MAPP (50 μM) treatment or from addition of 100 μM synthetic C16 ceramide induces apoptosis in neutrophil cultures via caspase-3 activation.2

1.White-Gilbertson, S., Mullen, T., Senkal, C., et al.Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase 3 in colon cancer cellsOncogene28(8)1132-1141(2009) 2.Seumois, G., Fillet, M., Gillet, L., et al.De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosisJ. Leukoc. Biol.81(6)1477-1486(2007)

レビュー

Review for C16 Ceramide-d7 (d18:1-d7/16:0)

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for C16 Ceramide-d7 (d18:1-d7/16:0)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.